1. Home
  2. ADVM
  3. ADVM News

Latest Adverum Biotechnologies Inc. (ADVM) News on November 5, 2025

ADVM

MT Newswires

7 days ago

Mizuho Cuts Price Target on Adverum Biotechnologies to $5.50 From $12, Keeps Outperform Rating

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?
ADVM

Zacks

7 days ago

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree?

ADVM

MT Newswires

8 days ago

RBC Raises Price Target on Adverum Biotechnologies to $4 From $3, Keeps Sector Perform, Speculative Risk

ADVM

MT Newswires

11 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

ADVM

MT Newswires

11 days ago

Sector Update: Health Care Stocks Advance Friday Afternoon

ADVM

MT Newswires

11 days ago

Sector Update: Health Care

ADVM

MT Newswires

12 days ago

Adverum Biotechnologies Buyout by Eli Lilly Represents 'Best Possible Outcome' for Company, Mizuho Says

ADVM

MT Newswires

12 days ago

Top Midday Stories: Stocks Rise After Lower-Than-Expected CPI; Intel Q3 EPS, Revenue Top Expectations

Eli Lilly to Acquire Eye Gene Therapy Developer Adverum Biotechnologies
ADVM

MT Newswires

12 days ago

Eli Lilly to Acquire Eye Gene Therapy Developer Adverum Biotechnologies

Eli Lilly to buy Adverum, General Dynamics stock hits new record
ADVM

Yahoo Finance Video

12 days ago

Eli Lilly to buy Adverum, General Dynamics stock hits new record

ADVM

MT Newswires

12 days ago

Eli Lilly to Acquire Adverum Biotechnologies for Up to $12.47 a Share

Lilly to Acquire Adverum Biotechnologies
ADVM

PR Newswire

12 days ago

Lilly to Acquire Adverum Biotechnologies

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year
ADVM

Simply Wall St.

a month ago

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners may be pleased with recent gains after 28% loss over the past year

ADVM

MT Newswires

4 months ago

Mizuho Cuts Price Target on Adverum Biotechnologies to $12 From $16, Keeps Outperform Rating

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

5 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Will Tesla have to play catch up to Waymo's robotaxis?
ADVM

Yahoo Finance Video

5 months ago

Will Tesla have to play catch up to Waymo's robotaxis?

Why Scott Bessent wants to make it easier for banks to own Treasurys
ADVM

Yahoo Finance

5 months ago

Why Scott Bessent wants to make it easier for banks to own Treasurys

Statement by Minister Guilbeault on Portuguese Heritage Month
ADVM

CNW Group

5 months ago

Statement by Minister Guilbeault on Portuguese Heritage Month

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population
ADVM

PR Newswire

5 months ago

Thyme Care Triples Its Multidisciplinary Care Team with Increased Focus on Often-Overlooked Survivorship Population

ADVM

GlobeNewswire

5 months ago

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry
ADVM

GlobeNewswire

5 months ago

EKOUAER Launches Wedding Season Special Edition and Joins The Knot Registry

Man Utd sign Brazil forward Cunha from Wolves
ADVM

AFP

5 months ago

Man Utd sign Brazil forward Cunha from Wolves

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins
ADVM

Moneywise

5 months ago

‘All the crypto cowboys are gone’: Kevin O’Leary says the sector is safe now and is backing stablecoins

ADVM

MT Newswires

6 months ago

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk

ADVM

Associated Press Finance

6 months ago

Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights
ADVM

GlobeNewswire

6 months ago

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

3 Penny Stocks Under $300M Market Cap To Consider
ADVM

Simply Wall St.

6 months ago

3 Penny Stocks Under $300M Market Cap To Consider

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

6 months ago

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM

Argus Research

6 months ago

Daily – Vickers Top Buyers & Sellers for 04/29/2025

ADVM

MT Newswires

6 months ago

Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing

ADVM

MT Newswires

6 months ago

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating

ADVM

MT Newswires

7 months ago

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk

ADVM

Associated Press Finance

7 months ago

Adverum Biotechnologies: Q4 Earnings Snapshot

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
ADVM

GlobeNewswire

7 months ago

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

7 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
ADVM

GlobeNewswire

7 months ago

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
ADVM

GlobeNewswire

8 months ago

Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

ADVM

MT Newswires

8 months ago

Adverum Biotechnologies Insider Bought Shares Worth $1,439,087, According to a Recent SEC Filing

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

8 months ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference
ADVM

GlobeNewswire

8 months ago

Adverum Biotechnologies to Participate in the Cowen 45th Annual Health Care Conference

3 US Penny Stocks With Market Caps Below $400M
ADVM

Simply Wall St.

9 months ago

3 US Penny Stocks With Market Caps Below $400M

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
ADVM

GlobeNewswire

9 months ago

Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ADVM

MT Newswires

a year ago

Mizuho Securities Cuts Price Target on Adverum Biotechnologies to $16 From $20, Outperform Rating Maintained

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ADVM

MT Newswires

a year ago

Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Announces Webcast to Report 52-Week LUNA Phase 2 Clinical Data and 4-Year OPTIC Clinical Data, and to Provide Key Pivotal Program Design Elements

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
ADVM

Zacks

a year ago

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates

ADVM

Associated Press Finance

a year ago

Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
ADVM

Zacks

a year ago

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
ADVM

Zacks

a year ago

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?
ADVM

Zacks

a year ago

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High?

ADVM

MT Newswires

a year ago

Mizuho Trims Price Target on Adverum Biotechnologies to $20 From $22, Keeps Outperform Rating

ADVM

MT Newswires

a year ago

Truist Adjusts Price Target on Adverum Biotechnologies to $40 From $60, Maintains Buy Rating

ADVM

MT Newswires

a year ago

RBC Adjusts Price Target on Adverum Biotechnologies to $12 From $15, Maintains Sector Perform Rating, Speculative Risk

ADVM

Associated Press Finance

a year ago

Adverum Biotechnologies: Q2 Earnings Snapshot

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD

ADVM

MT Newswires

a year ago

Adverum Biotechnologies Insider Bought Shares Worth $613,470, According to a Recent SEC Filing

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?
ADVM

Zacks

a year ago

Is Adverum Biotechnologies (ADVM) Stock Outpacing Its Medical Peers This Year?

ADVM

MT Newswires

a year ago

Chardan Research Adjusts Adverum Biotechnologies' PT to $40 From $4, Maintains Buy Rating

ADVM

MT Newswires

a year ago

Adverum Reports Positive Interim Results in Study of Investigational Wet AMD Drug

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet
ADVM

Zacks

a year ago

Wall Street Analysts Think Adverum Biotechnologies (ADVM) Could Surge 290.54%: Read This Before Placing a Bet

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies to Host Webcast to Review Clinical Data from the 26-Week Interim Analysis of the Ongoing LUNA Phase 2 Trial in Wet AMD Being Presented at ASRS Annual Meeting

ADVM

MT Newswires

a year ago

Oppenheimer Initiates Coverage on Adverum Biotechnologies With Outperform Rating, $25 Price Target

Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies to Participate in TD Cowen’s Genetic Medicines & RNA Summit

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
ADVM

GuruFocus.com

a year ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

ADVM

Energy Global

a year ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
ADVM

USA TODAY

a year ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
ADVM

Business Wire

a year ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
ADVM

Business Wire

a year ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
ADVM

GlobeNewswire

a year ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
ADVM

Reuters

a year ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
ADVM

GlobeNewswire

a year ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of Directors

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
ADVM

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

ADVM

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
ADVM

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

ADVM

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
ADVM

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
ADVM

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
ADVM

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
ADVM

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

ADVM

GuruFocus.com

a year ago

Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
ADVM

Zacks

a year ago

Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)

ADVM

Associated Press Finance

a year ago

Adverum Biotechnologies: Q1 Earnings Snapshot

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
ADVM

GlobeNewswire

a year ago

Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
ADVM

Zacks

a year ago

Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
ADVM

GlobeNewswire

2 years ago

Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ADVM

Zacks

2 years ago

Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

ADVM

MT Newswires

2 years ago

HC Wainwright Starts Adverum Biotechnologies With Buy Rating, $30 Price Target

ADVM

MT Newswires

2 years ago

Mizuho Adjusts Price Target on Adverum Biotechnologies to $22 From $40 After Model Update, Maintains Buy Rating

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
ADVM

GlobeNewswire

2 years ago

Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Share on Social Networks: